Clear cell adenocarcinoma (CCAC) of the uterine cervix is a rare variant of cervical adenocarcinoma accounting for approximately 4-9% of this disease. Given the rarity of this pathological entity, the optimal treatment management is far from being defined. Earlier evidence suggested that the prognosis of patients bearing cervical CCAC is worse than with other histotypes, thus making the investigation of multimodal treatment strategies clinically worthwhile. Herein, we report the first case of locally advanced, large size cervical CCAC in a young woman who was triaged to concomitant chemoradiotherapy followed by radical surgery and experienced a pathologically assessed optimal response to this multimodal approach.

Keywords:
Advanced clear cell adenocarcinoma, Chemoradiation, Multimodal approach, Radical surgery, Uterine cervix
1.
Saigo PE, Cain JM, Kim WS, Gaynor JJ, Johnson K, Lewis JL: Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 1986;57:1584-1593.
2.
Matias-Guiu X, Lerma E, Prat J: Clear cell tumors of the female genital tract. Semin Diagn Pathol 1997;14:233-239.
3.
Melnick S, Cole P, Anderson D, Herbst A: Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med 1987;316:514-516.
4.
Hanselaar A, van Loosbroek M, Schuurbiers O, Helmerhorst T, Bulten J, Bernheim J: Clear cell adenocarcinoma of vagina and cervix. An update of central Netherlands registry showing twin age incidence peaks. Cancer 1997;79:2229-2236.
5.
Reich O, Tamussino K, Lahousen M, Pickel H, Haas J, Winter R: Clear cell carcinoma of the uterine cervix: pathology and prognosis in surgically treated stage IB-IIB disease in women not exposed in utero to diethylstilbestrol. Gynecol Oncol 2000;76:331-335.
6.
Chan KKL, Ip P, Kwong P, Tam KF, Ngan HYS: A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix. Int J Gynecol Cancer; 2008;18:559-563.
7.
Ansari DO, Horowitz IR, Katzenstein HM, Durham MM, Esiashvili N: Successful treatment of an adolescent with locally advanced cervicovaginal clear cell adenocarcinoma using definitive chemotherapy and radiotherapy. J Pediatr Hematol Oncol 2012;34:174-176.
8.
Ferrandina G, Margariti PA, Smaniotto D, Petrillo M, Salerno MG, Fagotti A, Macchia G, Morganti AG, Cellini N, Scambia G: Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol 2010;119:404-410.
9.
Chan KK, Ip P, Kwong P, Tam KF, Ngan HY: A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix. Int J Gynecol Cancer 2008;18:559-563.
10.
Togami S, Kasamatsu T, Sasajima Y, Onda T, Ishikawa M, Ikeda S, Kato T, Tsuda H: Serous adenocarcinoma of the uterine cervix: a clinicopathological study of 12 cases and a review of the literature. Gynecol Obstet Invest 2012;73:26-31.
11.
Ferrandina G, Carbone A, Macchia G, Petrillo M, Lucidi A, Morganti AG: A complete pathological response to treatment in a young patient with locally advanced minimal deviation adenocarcinoma of the uterine cervix undergoing chemoradiation followed by radical surgery. Gynecol Obstet Invest 2011;72:141-144.
12.
Waggoner SE, Anderson SM, Luce MC, Takahashi H, Boyd J: p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix. Gynecol Oncol 1996;60:339-344.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.